Skip to content
Stay curious ↗

Follow your curiosity.

Try “brain”, “genomics”, or another subject you follow.

Today/Oncology
Oncology · The big question

Live Gut Bacteria Show Early Promise in Lung Cancer Treatment

Phase I trial of CJRB-101 plus pembrolizumab in patients with metastatic non-small cell lung cancer, head and neck squamous cell carcinoma and melanoma.

PubMed2 min readAI-assisted summary
Editorial illustration for Phase I trial of CJRB-101 plus pembrolizumab in patients with metastatic non-small cell lung cancer, head and neck squamous cell carcinoma and melanoma.
Editorial illustration

Summary

Scientists are exploring a fascinating new angle in the fight against cancer: using live gut bacteria to help the immune system attack tumors. Researchers recently tested a new treatment called CJRB-101, a live biotherapeutic pill made from a specific strain of bacteria. In early laboratory models of non-small cell lung cancer, combining this bacteria pill with pembrolizumab, a standard immunotherapy drug, worked better to shrink tumors than the immunotherapy drug alone.

The secret to this bacterial boost appears to be a shift in the immune system. Lab tests suggest the treatment changes certain immune cells from a state that protects the tumor into a state that fights it, while also activating specialized killer T cells. Moving from the lab to the clinic, a first-in-human Phase I trial involving 42 patients showed that taking these bacterial capsules alongside immunotherapy was safe and well-tolerated, with no severe toxicities that required stopping or lowering the dose.

The initial signs of effectiveness are encouraging but highly specific. In a small group of 12 patients who had never received immunotherapy before, 58 percent saw their tumors respond to the combination, keeping their cancer from progressing for a median of nine months. However, the treatment was largely ineffective for the 22 patients whose tumors had already grown resistant to standard immunotherapy. Because this is an open-label study with very small patient groups, researchers caution that we need much larger trials to draw definitive conclusions about its clinical power.

Why it matters.

Immunotherapy has transformed how we treat advanced cancers, but it still fails to work for everyone. Scientists have increasingly suspected that a patient's gut microbiome, the vast community of bacteria living in the digestive tract, plays a critical role in determining whether these powerful treatments will succeed. If a safe, live bacterial pill can consistently prime the immune system to accept immunotherapy, it could become a simple way to make standard cancer drugs work for far more people.

While this early data shows we cannot yet rescue patients who have already developed resistance to immunotherapy, the strong response in newly treated patients is a vital stepping stone. Non-small cell lung cancer remains a leading cause of cancer deaths worldwide. Finding a low-toxicity method to extend progression-free survival to nine months in these specific patients offers a compelling new direction for future oncology research and drug development.

From the source

The story in numbers.

Total patients enrolled
42
ORR in ICI-naïve NSCLC (PD-L1 >50%)
58%
Grade >3 treatment-related adverse events
0
Keep the context

Follow the evidence.

This AI-assisted summary is a starting point. Read the original reporting for its methods, scope, and limitations.

Your next discovery.

Keep exploring ↗
Oncology

Targeted Drug Spares Lymphoma Patients from Stem Cell Transplants

Mantle cell lymphoma is a challenging type of blood cancer. For years, the standard treatment for younger, relatively fit patients has been a heavy dose of chemotherapy followed by an autologous stem cell transplant. This transplant process involves collecting a patient's own healthy stem cells, delivering high-dose chemotherapy to wipe out the cancer, and then returning the healthy cells to help the body recover. It is an intense procedure that can be incredibly hard on the body. A recent major clinical trial followed 870 patients across Europe and Israel for over four years to see if adding a targeted daily pill called ibrutinib could improve outcomes. Researchers split the patients into three groups to test different combinations of standard chemotherapy, ibrutinib, and stem cell transplants. They found that adding ibrutinib significantly boosted both how long patients lived overall and how long they lived without their cancer returning or worsening. The most welcome discovery was that the grueling stem cell transplant may no longer be necessary. The group that received chemotherapy and ibrutinib but skipped the transplant did just as well as the group that received all three. Adding the transplant to the ibrutinib regimen provided no extra survival benefit but significantly increased the risk of severe side effects, like dangerous drops in healthy blood cells. It is worth noting that this study only looked at untreated patients aged 18 to 65, so the findings might not apply to older or less fit individuals.

PubMed2 min read
Oncology

Colorectal Cancer Prepares to Spread Earlier Than We Thought

For anyone diagnosed with cancer, the most dangerous moment is when the disease begins to spread to new areas of the body, a process known as metastasis. Scientists have long wondered exactly when and how a localized tumor gains the ability to travel. In a new study looking at colorectal cancer, researchers made a surprising discovery. They found that tumors actually develop the necessary tools to spread much earlier than previously believed. By studying patient samples and miniature lab-grown tumors called organoids, the research team looked at how tumor cells behave at a microscopic level. They discovered that many early-stage tumors adopt a highly flexible condition called an oncofetal state. Normally, this shapeshifting ability is only seen in advanced, late-stage cancers. But the researchers found that these flexible cancer cells were already gathering at the edges of early tumors. There, they mingle with normal connective tissue cells known as fibroblasts, which actively encourage the cancer cells to become even more adaptable and ready to move. However, simply having these flexible cells is not enough to guarantee the cancer will spread, since not all early-stage tumors actually go on to metastasize. The researchers investigated what pushes the tumor over the edge. They ruled out new genetic mutations as the trigger. Instead, their findings suggest that a cancer cell's ability to hide from the immune system might be the final key to unlocking its deadly spread.

Nature Genetics2 min read
Oncology

New nanoparticle tech breaks down tumor shields to boost immunity

Tumors have a sneaky way of hiding from the body's immune system. They wrap themselves in a dense, sugary protective coating known as the glycocalyx. This shield is packed with mucins, which are thick proteins that physically block immune cells and modern cancer treatments from reaching the target. While scientists have discovered a bacterial enzyme called StcE that can chew through this sticky barrier, using it as a drug has been difficult. Injecting the free enzyme directly into the body causes unwanted toxic side effects and triggers severe immune reactions. To solve this problem, researchers engineered a clever delivery system using cell membrane fusion nanovesicles, which are essentially microscopic bubbles made from natural cell materials. They equipped these tiny delivery vehicles with both the barrier-breaking StcE enzyme and specialized targeting molecules called CD47 nanobodies. These nanobodies act like a homing device that seeks out cancer cells. By using this biomimetic delivery platform, the enzyme successfully digests the protective sugary shield precisely at the tumor site, avoiding the widespread toxicity and safety issues of the free enzyme. With the barrier cleared away, the immune system gets a much clearer shot at the tumor. The researchers found that removing the mucin shield allowed the nanobodies to bind tightly to the cancer cells, sounding the alarm for the body's natural defenses. The treatment successfully suppressed tumor growth and stopped the cancer from spreading by radically remodeling the environment around the tumor, bringing in a flood of protective immune cells.

PubMed2 min read

A little science goes a long way.

Clear, thoughtful biotech briefings. In your inbox three times a week.

Stay curious. Subscribe free ↗